Clinical trial · no report yet · Phase 2
INTerpath-004
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
- NCT06307431 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 12 | |
| Podcasts | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004).
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Renal Cell Carcinoma
- Interventions
- Intismeran autogene; Pembrolizumab; Placebo
- Arms
- Intismeran autogene + Pembrolizumab · Experimental
- Placebo + Pembrolizumab · Active comparator
- Enrollment
- 272 (estimated)
- Primary outcomes
- Disease-Free Survival (DFS)
- Sponsor
- Merck Sharp & Dohme LLC with ModernaTX, Inc.
- Start
- Apr 10, 2024
- Primary completion
- Jan 8, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06307431 · updated Jul 13, 2026